Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 51.2 CHF -0.58%
Market Cap: 620.6m CHF

Basilea Pharmaceutica AG
Total Other Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Basilea Pharmaceutica AG
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Basilea Pharmaceutica AG
SIX:BSLN
Total Other Income
-CHf1.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-22%
ADC Therapeutics SA
NYSE:ADCT
Total Other Income
$12.2m
CAGR 3-Years
208%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Total Other Income
$89.8m
CAGR 3-Years
89%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Total Other Income
-CHf810k
CAGR 3-Years
70%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Basilea Pharmaceutica AG
Glance View

Market Cap
628.9m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
74.89 CHF
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Basilea Pharmaceutica AG's Total Other Income?
Total Other Income
-1.3m CHF

Based on the financial report for Jun 30, 2025, Basilea Pharmaceutica AG's Total Other Income amounts to -1.3m CHF.

What is Basilea Pharmaceutica AG's Total Other Income growth rate?
Total Other Income CAGR 10Y
-22%

Back to Top